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Development of acquired chemoresistance renders a challenge in breast cancer therapy. Aurora kinases, a family of 
serine/threonine mitotic kinases play pivotal roles in the acquirement of chemoresistance. Aurora A is intricately associated 
with mitotic events and is overexpressed in different cancers including breast cancer. Amplification or overexpression 
Aurora A confers chemoresistance and are considered as a promising therapeutic target in cancers. Therefore, targeting 
Aurora A by natural means particularly by using Phenethyl isothiocyanate (PEITC), a natural isothiocyanate might be an 
effective strategy for reversing resistance towards chemotherapeutics. The present study investigated the modulatory role of 
PEITC on Aurora A and their downstream target proteins in breast adenocarcinoma cell line (MCF-7) and its paclitaxel-
resistant counterpart; designated as MCF-7Pacli/R. Paclitaxel resistance was warranted by P-gp1, MRP1, Ki-67 
overexpression, rhodamine 123 accumulations and upregulation of Aurora-A along with phospho-IκBα. Multidrug 
resistance was confirmed by MTT assay. Western blotting, RT-PCR analysis revealed overexpression of Aurora-A in MCF-
7Pacli/R cells; which was eventually diminished by PEITC. PEITC by targeting Aurora A and their downstream proteins 
(phospho-p53, phospho-IκBα) acted as a resistance-modifying agent and ultimately led to paclitaxel- induced apoptosis. 
These findings demonstrated that PEITC reverses chemoresistance by regulating Aurora A and restores chemosensitivity 
towards paclitaxel. 
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The development of acquired chemoresistance is a 
major challenge to combat the recurrence of breast 
cancer in spite of the recent advancement in the 
treatment modality. Many molecular markers have 
been identified to date that is responsible for the 
multidrug resistance in cancer cells and its relapse1-3. 
Apart from the known molecular markers like  
P-glycoprotein 1 (P-gp1), Multidrug resistance- 
associated protein 1 (MRP1), ATP-binding cassette 
sub-family G member 2 (ABCG2) (drug efflux 
markers) responsible for decreasing efficacy of the 
drug, organic anion transporter (OAT), organic cation 
transporter (OCT) (SLC family of drug influx 
markers) and certain other markers belonging to the 
family of mitotic kinases like Aurora A and Aurora B 
(cell cycle regulatory kinase protein) are also 
contributing a major role in acquirement of 
chemoresistance4-10. Several mitotic and non-mitotic 
roles of Aurora- A have been identified that are 
directly associated with the resistance to 
chemotherapy11-17. In human, evolutionary conserved 
three members of Aurora family (Aurora A, B, and C) 
have been identified and interestingly they almost 
share the conserved catalytic domain, indicating their 
origin from a common ancestor gene10,18. Aurora-A, 
located on chromosome 20q13.2 is reported to be 
aberrantly expressed in breast cancer19. Majorly being 
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Mouse double minute 2 homolog; NF-κB, Nuclear Factor kappa-
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kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; 
MCF-7, Michigan Cancer Foundation-7; MCF-7Pacli/R, 
Paclitaxel resistant MCF-7; MEM, Minimum Essential Medium 
Eagle; FBS, Fetal Bovine Serum; 5-FU, 5-fluorouracil; MTT, 4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltet razolium Bromide; PBS, 
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Inhibitory Concentration; PCR, Polymerase Chain Reaction; EtBr, 
ethidium bromide; PI, Propidium Iodide; BCIP/NBT, 5-bromo-4-
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a centrosomal protein, Aurora A functions primarily 
in centrosome maturation and separation. In addition 
to its involvement in the centrosome, some other 
noteworthy functions of Aurora A are mitotic entry 
and exit, bipolar spindle formation and 
cytokinesis18,19. Some of the notable downstream 
target proteins of Aurora A are p53, BRCA1 or Breast 
cancer type 1 susceptibility protein and IκBα20-22. 
Aurora A phosphorylates p53 at serine 315 and 215 
residues, indicating its two different fates. 
Phosphorylation at serine 315 residue of p53 protein 
by Aurora A leads to MDM2-mediated proteasomal 
degradation. Phosphorylation, on the contrary at 
serine 215 residue of p53 results into lesser DNA 
binding activity of the tumor suppressor protein to the 
DNA responsive element of target gene21,23. Another 
important protein of concern is IκBα. Aurora A 
phosphorylates IκBα at serine 32 and 36 residue and 
releases NF-κB, which eventually leads to enhanced 
expression of P-gp120,24. NF-κB, being a transcription 
factor conversely promotes survival and 
chemoresistance in solid tumor25-27.  
Therefore, targeting Aurora A would be a rational 
strategy in the treatment of breast cancer. Several 
small-molecule inhibitors of Aurora kinases are in 
trials, but they elicit serious toxicity within cells. 
Therefore, using natural products in cancer research is 
considered nowadays as a powerful approach as these 
natural compounds possess unique structures and 
mechanisms of actions28. These compounds having 
low cost, easy availability and minimal or no toxicity, 
are used in combination with chemotherapeutic drugs to 
minimize the toxicity. Accumulating epidemiological 
evidence indicates an inverse correlation between the 
intake of cruciferous vegetables and the occurrence of 
malignant tumors. Phenethyl isothiocyanate (PEITC), an 
important member of the family of cruciferous 
vegetables showed interesting anti-tumor properties on 
several cancer cell lines either alone or in combination 
with chemotherapeutics29-33. Therefore, the use of dietary 
phytochemicals like PEITC possibly is a relevant 
approach to restore chemosensitivity towards common 
chemotherapeutics and to minimize drug toxicity as 
well. 
 
Materials and Methods  
Development and Isolation of Cell Line 
Human breast adenocarcinoma (MCF-7) cell line 
was obtained from National Centre for Cell Science 
(NCCS), Pune. A paclitaxel- resistant cell line was 
derived from the parental MCF-7 cells by treating 
those cells with increasing concentration of paclitaxel 
with an initial dose of 1 nM. Cells were maintained in 
each concentration for at least 6 passages and finally, 
a colony has been isolated at 120 nM. The isolated 
resistant subline has been designated as MCF-7Pacli/R. 
Before experimentation, MCF-7Pacli/R cells were 
maintained in drug-free medium for at least one week. 
 
Maintenance of Cell Lines 
MCF-7 and its paclitaxel-resistant counterpart 
MCF-7Pacli/R were maintained in Minimum Essential 
Medium Eagle (MEM) supplemented with 10% heat-
inactivated Fetal Bovine Serum (FBS) and antibiotics 
(gentamycin 40 µg, penicillin 100 units, streptomycin 
10 µg/mL). Cells were maintained at 37C in a 
humidified CO2 incubator having 5% CO2/95% air. 
  
Rhodamine 123 Accumulation Assay 
A fluorescent dye, Rhodamine 123 is one of the 
substrates for P-gp1. For confirming resistance 
towards paclitaxel and enhanced P-gp1 activity 
Rhodamine 123 assay kit was used. Briefly, MCF-7 
and MCF-7Pacli/R cells were incubated with Rhodamine 
123 (5 μM) for 30 min at 37C in the presence or 
absence of 1 μM Zosuquidar (SIGMA # SML1044), a 
specific P-gp1 inhibitor. Treated cells were thereafter 
washed with Phosphate Buffered Saline (PBS), lysed 
and Rhodamine 123 was quantitated using 
spectrofluorimeter (Varian) with excitation and 
emission wavelength of 485 nm and 535 nm, 
respectively.  
 
Determination of Multidrug Resistance  
MTT (4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltet 
razolium Bromide) assay was performed to verify 
whether the isolated paclitaxel-resistant cell was 
resistant to multiple drugs. Cells at a density of 1 × 
104 were seeded in each of the 96 well plates and 
exponentially growing cells were treated in triplicate 
with logarithmic doses of either paclitaxel or 
doxorubicin or 5-fluorouracil (5-FU) for 24 h. MTT 
solution 50 µL (1.2 mg/mL in water) was added to 
each of the 96 wells and incubated for 5 h. Finally, 
after centrifugation, DMSO was added to dissolve 
MTT-formazan product (purple colored) and 
estimated by measuring absorbance at 570 nm in an 
ELISA plate reader.  
 
Computation of IC50 value by MTT assay 
MTT assay was furthermore carried out for 
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determination of (a) IC50 value (the half- maximal 
inhibitory concentration) of PEITC and (b) reversal of 
acquired paclitaxel resistance in presence of PEITC. 
(a) Exponentially growing parental and resistant 
cells (1 × 104/well) seeded in 96 well plates were 
treated with increasing concentration of PEITC 
(Sigma-Aldrich: catalogue no# 253731-5G) for 24 h. 
MTT assay was carried out following the protocol 
mentioned previously. 
(b) Both MCF-7 and MCF-7Pacli/R were seeded in 
96 well plates (1 × 104/well). Confluent cells were 
treated with or without PEITC along with logarithmic 
doses of paclitaxel for another 24 h. MTT assay was 
carried out.  
 
Western Blotting 
Whole-Cell lysate was prepared using the lysis 
buffer. Protein concentrations were quantified 
following Lowry’s method. Equally loaded proteins 
from cell lysates were then electrophoresed on  
SDS-polyacrylamide gel using electrophoresis buffer 
(Tris: 25 mM, glycine: 192 mM, SDS: 20%) and 
separated proteins were electro-transferred to 
nitrocellulose membranes using transfer buffer  
(Tris: 250 mM, glycine: 192 mM, methanol: 10%) 
and blocked in 5% BSA. The membranes were then 
incubated with primary antibody to react overnight at 
4C; thereafter washed with TBST (Tris Buffered 
Saline with Tween20) thrice followed by treatment 
with alkaline phosphatase-conjugated anti-mouse IgG 
or anti-rabbit IgG (1:1000 dilutions in TBS) 
depending on the specificity of primary antibodies. 
Membranes were washed properly with TBST and 
treated with BCIP/NBTto visualize the proteins. The 
experiment was repeated three times. 
The antibodies used were: MRP1 (GeneTex, 
GTX116046, 1:1000) P-gp1 (GeneTex, GTX108370, 
1:1000), ABCG2 (GeneTex, GTX100437, 1:1000) 
Ki-67 (GeneTex, GTX26526, 1:1000), phospho-
Aurora A (Thr288, 1:1000) from BioLegend, 
phospho-p53 (S315, 1:1000) GTX50164, p53 
(GTX70218, 1:1000), β-actin (GTX629630, 1:1000), 
Phospho-IκBα (Ser32) antibody from CST (1:1000). 
Enzyme commission (EC) number of Aurora Kinase 
A enzyme is EC:2.7.11.1. 
 
Semi-quantitative Reverse Transcription PCR analysis  
(RT-PCR)  
Isolation of total cellular RNA was performed using 
the RNA queous 4PCR kit (Ambion/Applied 
Biosystem) according to the manufacturer’s instructions. 
cDNA was synthesized from 2 μg of total RNA using 
the RetroScript kit (Ambion/Applied Biosystem). The 
cDNA was amplified by PCR using forward and reverse 
primer sequences of Aurora A (Aurora A: Forward 
primer 5-AATTGCAGATTTTGGGTGGT-3; Reverse 
primer 5-AAACTTCAGTAGCATGTTCCTGTC-3.  
β-actin/ACTB gene (Forward primer 5-CTGGAAC 
GGTGAAGGTGACA-3; Reverse primer 5-AAGGGA 
CTTCCTGTAACAACGCA-3) was used as loading 
control. PCR product was analyzed by electrophoresis 
on 2% agarose gel and visualized by staining with 
ethidium bromide (EtBr) under Gel Documentation 
System.  
 
TUNEL assay 
Harvested cells were smeared on the poly-L lysine 
coated slides and fixed with paraformaldehyde. After 
fixation of cells, the glass slides were washed with 
PBS (twice) followed by addition of 50 μL of the 
labeling reaction mixture (prepared as per information 
provided with the TaKaRa in situ Apoptosis Detection 
kit) (Catalogue no# MK500) and incubated afterward 
in a humidified chamber at 37C for 90 min. The 
reaction was terminated by washing with PBS and 
finally, the slides were mounted and detected under a 
fluorescence microscope. 
 
Morphological examination of cells by Propidium Iodide (PI) 
Treated cells were harvested, washed with PBS and 
centrifuged and to the pellet PI (Sigma-Aldrich: 
catalogue no# P4170-10MG) was added (final:  
50 µg/mL). Cells were then incubated in the dark at 
RT for 10 min. Treated cells along with control one 
was spread over slides, covered with coverslips, and 
examined under the fluorescent microscope. Number 
of apoptotic and normal cells was counted in each 
slide. The ratio of apoptotic cell to normal cell was 
calculated and the apoptotic index was plotted 
graphically.  
 
Statistical analysis 
Statistical analysis was carried out using GraphPad 
Prism Software. A P-value <0.005 was considered 
statistically significant. 
 
Results 
Confirmation of acquired chemoresistance towards paclitaxel 
During the development of paclitaxel resistant 
subline, a stepwise increasing dose of the drug has 
been used. In each of the incremental stages, gradual 
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elevations in the expressions of the members of ATP-
binding cassette (ABC) transporter family proteins 
(MRP1, P-gp1, ABCG2) were observed. Protein 
expression of proliferative (Ki-67) marker has also 
been checked. Paclitaxel concentration was increased 
gradually up to 120 nM and cells were finally isolated 
at that concentration. Paclitaxel dose was increased 
beyond 120 nM but the expressions of drug efflux 
pumps remain unaltered from 120 nM onwards. Cells 
were allowed to grow in drug free medium for  
4 weeks for ascertaining resistance in an isolated 
subline of MCF-7 and thereafter designated as MCF-
7Pacli/R (Fig. 1A). Protein expressions of efflux pumps 
and proliferative markers as obtained from western 
blotting were quantified using software and plotted 
graphically (Fig. 1B). To ensure acquired 
chemoresistance towards paclitaxel, P-gp1 activity 
was measured by Rhodamine 123 assay. Rhodamine 
123 is the substrate for P-gp1; as the protein expels 
out the dye. Results revealed that the accumulation of 
Rhodamine 123 in MCF-7Pacli/R was very poor in 
comparison to parental MCF-7; reflecting P-gp1 
mediated efflux of Rhodamine in resistant 
counterpart. However, the accumulation of 
Rhodamine in MCF-7Pacli/R was found to be increased 
when the resistant subline was treated with 
Zosuquidar (1 μM), a specific P-gp1 inhibitor, for  
30 min at 37C (Fig. 1C).  
To confirm the resistance of MCF-7Pacli/R towards 
other chemotherapeutics, a multidrug resistance 
assay was performed using MTT assay. Absorbance 
was taken at 570 nm. Results showed resistance 
towards the respective chemotherapeutic drugs 
(Paclitaxel, Doxorubicin, and 5-Fluorouracil) in 
 
 
Fig. 1 — Confirmation of acquired paclitaxel resistance in MCF-7Pacli/R subline. (A) Protein expressions of drug efflux pumps 
(P-gp1, MRP1, ABCG2) and proliferative marker (Ki-67) during the developmental process of paclitaxel resistant cell line, treated with 
stepwise increasing doses of paclitaxel. β-actin was used as a loading control; (B) Corresponding band intensities were plotted graphically 
after calculating intensities using Image Master Software. Intensities were normalized to β-actin. 
P values were calculated and have been displayed; and (C) Rhodamine 123 accumulation in parental MCF-7 and MCF-7Pacli/R. Cells were 
exposed to Rhodamine 123 (5 μM) for 30 min at 37C in the absence of Zosuquidar, a specific inhibitor of P-gp1 or pretreated with 
Zosuquidar (1 μM) for 30 min at 37C, followed by Rhodamine 123 treatment. Accumulation was quantified spectrofluorimetrically. 
Data were represented as fluorescence arbitrary units. Values represent the mean ± SD of three independent experiments (n=3). P values 
were significant as calculated and were shown in the figure 
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resistant subline in comparison to parental one  
(Fig. 2A & B). Based on MTT results IC50 values 
were calculated and represented in a table (Table 1). 
The values are in agreement with the development of 
a paclitaxel resistant subline, which is not only 
resistant to paclitaxel but also other 
chemotherapeutics. Next, it was examined whether 
Aurora A, in addition to ABC transporters, has  
any contributory role in the development of 
paclitaxel resistance. For this purpose, protein 
expressions of phospho-Aurora A (Thr 288)  
were observed at each of the incremental steps. 
Expression of phospho-IκBα (Ser 32) was also 
checked furthermore as the protein gets 
phosphorylated by Aurora A and it releases from 
NFκB (Fig. 3A). Band intensities were calculated 
accordingly using Image Master Software and 
depicted an increasing trend for both phospho-
Aurora A and phospho-IκBα with increasing 
concentrations of paclitaxel (Fig. 3B).  
 
Determination of IC50 and IC30 value of PEITC in parental 
and resistant subline 
Before look into the influence of PEITC in 
reversing chemoresistance, it is important to 
determine the IC50 and IC30 value of the compound in 
both parental and resistant sublines. For this purpose, 
Table 1 — IC50 values of different chemotherapeutic drugs as 
obtained from MTT assay after treatment for 24 h 
Drugs (µM) MCF-7 MCF-7Pacli/R 
Paclitaxel 2 28 
Doxorubicin 82 355 
5-Fluorouracil 60 337 
 
 
Fig. 2 — Acquired resistance towards different chemotherapeutic drugs as obtained from MTT assay after treatment for 24 h. MTT 
reduction assay was carried out after treatment of (A) MCF-7 and (B) MCF-7Pacli/R with different concentrations of paclitaxel, 
doxorubicin , and 5-Flurouracil (5-FU). Absorbance was taken at 570 nm. Values represent mean ± SE (n=3) 
 
 
 
Fig. 3 — Expressions of phospho-Aurora A (Thr 288) and phospho-IκBα (Ser32) during each of the incremental doses of paclitaxel 
treatment. (A) Cells were harvested in each incremental dose and subjected to western blot analysis. β-actin was used to ensure equal 
protein loading; and (B) Band intensities of both phospho-Aurora A (Thr 288) and phospho-IκBα (Ser32) were calculated using Image 
Master Software. Results were an average of three independent experiments. Values represented mean ± SD (n=3). P values as 
represented are significantly different compared with untreated counterparts 
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MTT assay was carried out after the treatment of cells 
with increasing concentrations of PEITC with a 
maximum concentration of 18 μM. The proliferation 
of MCF-7 and MCF-7Pacli/R were found to be inhibited  
significantly by PEITC in a concentration-dependent 
manner when cells were treated for 24 h. Based on 
MTT results, both IC30 and IC50 values were 
calculated (Fig. 4A & B) and an approximate dose of 
IC30 values was selected (5 μM) for experimental 
purpose and both parental and resistant cells were 
treated with that concentration.  
 
Role of PEITC as RMA  
After calculating IC50 values, it was intended to 
observe whether PEITC could reverse paclitaxel-
induced acquired chemoresistance. To achieve this 
goal, both parental and paclitaxel resistant sublines 
were co-treated with PEITC and paclitaxel for 24 h 
followed by MTT reduction assay. Absorbance was 
taken at 570 nm and data were shown (Fig. 4C).  
From the result obtained from MTT assay, the EC50 
value of paclitaxel was calculated in PEITC treated 
and untreated cells. EC50 values of paclitaxel 
decreased significantly when both  MCF-7 and MCF- 
7Pacli/R cells were treated with PEITC (Table 2). 
Reversal index (RI) which is the ratio of EC50 of the 
 
 
Fig. 4 — Determination of IC50 and IC30 values of PEITC and furthermore establishing PEITC as a resistance modifying agent. (A) MCF-7; 
(B) MCF-7Pacli/R cells were incubated with different concentrations of PEITC for 24 h. Cytotoxicity was measured by MTT reduction 
assay. The error bars indicated standard deviations of three samples; and (C) Both MCF-7 and MCF-7Pacli/R cells were treated with 
different logarithmic doses of paclitaxel for 24 h in the presence and absence of PEITC (5 µM). Cytotoxicity was measured by MTT 
reduction assay. The error bars indicated standard deviations of three samples. P values of PEITC treated cells were significant vs PEITC 
untreated controls 
Table 2 — Reversal of acquired resistance in breast  
cancer cells by PEITC. Values are mean ± SD, (n=3) 
Compound MCF-7  MCF-7Pacli/R 
 EC50 Pacli RI EC50 Pacli RI 
Compound (-) 2±0.2 - 28±1.8 - 
PEITC 0.2±0.03 10 5.3±0.5 5.28 
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chemotherapeutic drug alone to EC50 value of 
chemotherapeutic drug in presence of PEITC was 
then calculated. The values assertively indicated that 
PEITC was much more efficient in imparting 
sensitivity of resistant cells towards paclitaxel by 
reversing chemoresistance.  
 
Influence of PEITC on the expression profile of Aurora A in 
MCF-7Pacli/R subline 
Since PEITC was found to reverse the resistance 
towards paclitaxel, therefore it was felt interesting  
to understand the underlying mechanism by which 
PEITC is performing its function. To accomplish  
the objective, expression of phospho-Aurora A (Thr 
288) at protein as well as genetic levels were 
determined by western blot analysis and semi-
quantitative Reverse Transcriptase-PCR technique, 
respectively. Results indicated a time dependent 
inhibition of phospho-Aurora A in both the cell lines 
(Fig. 5A). Expression of mRNAs of Aurora A in 
presence of PEITC was found to diminish with time 
(Fig. 5B).  
 
 
Effect on downstream signaling proteins of Aurora A 
Next, it was attempted to find out whether PEITC, 
by inhibiting Auroras, could affect phosphorylation of 
p53 and IκBα, two important targets of Aurora A. 
Results revealed that untreated cells contained high 
levels of phospho-p53 at serine 315 residues. 
Treatment with PEITC reduced the phosphorylation 
status of the protein. The ratio of phospho p53 to total 
p53 was calculated in both parental and resistant cells 
(Fig. 6A). The results were analogous to those 
obtained after treatment with Aurora A inhibitor I 
(Sigma-Aldrich: catalogue no# SML0882-5MG) 
using a concentration of 3 nM (Fig. 6B).  
Next objective of the study was to look into the 
expression pattern of IκBα (p Ser 32) as it is a target 
protein of Aurora A. Western blotting followed by 
calculation of band intensities of IκBα (p Ser 32) 
showed significant fold decrease after treatment with 
PEITC. The result was comparable to that in Aurora A 
inhibitor I treated cells (Fig. 6C). This result probably 
indicated that diminished expression of IκBα (p Ser 32) 
is due to inhibition of Aurora A. All these results 
cumulatively pointed out the efficacy of PEITC in 
targeting Auroras and their downstream target proteins. 
 
PEITC augments apoptosis mediated by paclitaxel  
It was thereafter intended to observe whether 
PEITC by regulating Auroras and reversing 
chemoresistance could induce apoptosis in MCF-7 
and MCF-7Pacli/R cells. TUNEL assay was performed 
for the purpose. Briefly, exponentially growing cells 
were treated with 5 μM PEITC for 24 h. Cells were 
then harvested and smeared on poly-L lysine coated 
slides, stained with 50 μL labeling mixture for 
fluorescence microscopy and visualized at 20X 
magnification. Apoptotic cells (bright green colour) 
were identified in PEITC treated cells in both MCF-7 
and MCF-7Pacli/R cells but the extent of programmed 
 
 
Fig. 5 — Differential expressions of Aurora Kinase A in the presence or absence of PEITC. MCF-7 and MCF-7Pacli/R cells were treated 
with PEITC (5 µM) for different time periods. (A) Expression profile of active form of Aurora A protein was determined using the anti-
phospho-Aurora A (Thr 288) antibody; and (B) RT-PCR was performed to determine the mRNA expression in both the cells following 
the protocol mentioned in the materials and method section. β-actin was used as an internal loading control in both the experimental setup 
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cell death differs with cell type. PEITC treated MCF- 
 
 
 
 
Fig. 6 — Expressions of downstream target proteins of Aurora A in the presence and absence of PEITC. The treatment duration was 16 h. 
(A) Expression of phospho-p53 (Ser 315) residue and total p53 in whole cell lysate. β-actin was used as an internal loading control. (B) 
Band intensities were calculated and comparative band intensities (ratio) of phospho as well as total p53 proteins as obtained in presence 
of either PEITC or Aurora-A Inhibitor I was calculated and plotted graphically. Values were the average of three independent 
experiments. p values were calculated vs untreated cells and have been depicted. (C) Determination of fold change of phospho-IκBα (Ser 
32) after treatment with either PEITC or Aurora A inhibitor I. Values were mean of three independent experiments. P values vs control 
were calculated and have been illustrated 
 
 
 
Fig. 7 — PEITC induced paclitaxel mediated apoptosis. (A) Cells (MCF-7 and MCF-7Pacli/R) were incubated with PEITC (5 μM) for 24 h, 
and then harvested cells were processed and finally stained with a labeling reaction mixture that can label nicked end of DNA formed 
during apoptosis. Green fluorescence indicated apoptotic cells marked by a number of white arrows. Cells were visualized under 
fluorescence microscopy at 20X magnification; and (B) Apoptotic indices for MCF-7 and MCF-7Pacli/R cells treated with either PEITC (24 
h) and/or paclitaxel (24 h). For each treatment, 100 cells were scored at random under the fluorescent microscope and classified into 
apoptotic and non-apoptotic cells based on their characteristic features after staining with Propidium Iodide (PI). The ratio of apoptotic to 
non-apoptotic cells was designated as the apoptotic index. Values represented mean ± SD (n=100). Values were significant **P <0.0001 
vs untreated control 
 
7 cells underwent apoptosis as observed in the figure 
compared to the untreated MCF-7 cells. Conversely, 
very few MCF-7Pacli/R cells were directed to apoptosis 
when cells were treated with PEITC (Fig. 7A). Apart 
from the TUNEL assay, apoptotic cells were stained 
with Propidium Iodide (PI). In brief, cells were 
treated with either PEITC (5 µM), or paclitaxel  
(0.25 µM) or a combination of both. Harvested cells 
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were stained with PI and observed under the 
fluorescent microscope. The apoptotic index value 
was then calculated under a fluorescent microscope 
after PI staining. The result established that in 
combination treatment, PEITC promotes paclitaxel- 
induced apoptosis in both resistant and parental breast 
adenocarcinoma cells (Fig. 7B). 
 
 
Discussion 
Paclitaxel is considered as a first-line 
chemotherapeutic agent for the treatment of breast 
cancer34,35. Nonetheless, the efficacy of this drug is 
limited by the resistance, inevitably acquired due to 
long-term exposure7. Among several factors 
associated with acquired chemoresistance, Aurora 
kinases (particularly, Aurora A) are the most relevant 
ones. Aurora kinases play crucial roles in mitotic 
regulation18. Therefore the management of drug 
resistance by targeting Aurora kinases is an important 
approach for successful chemotherapy. The present 
study dealt with the development of a drug resistant 
subline from the parental MCF-7 using paclitaxel, a 
widely used chemotherapeutic for breast cancer. The 
resistant subline was initially characterized by 
observing the expressions of signature markers of 
chemoresistance like MRP1, P-gp1, ABCG2 and 
proliferative markers like Ki-67. The upregulation of 
these drug efflux transporters in resistant subline 
reinforced the assumption of acquired 
chemoresistance. Interestingly, Aurora A was found 
to be upregulated with incremental doses of 
paclitaxel; indicating its contributory role in the 
acquirement of chemoresistance. Aurora A 
phosphorylates IκBα at Ser 32, which in turn releases 
NF-κB that can translocate to the nucleus. That 
transcription factor directly influences P-gp1 
overexpression and thus confers chemoresistance20,24. 
Present findings are also in agreement with previous 
results as the uprising trend of phospho IκBα (Ser 32) 
was observed during the development of 
chemoresistant subline. Measurement of P-gp1 
activity and its inhibition by specific inhibitor 
Zosuquidar was carried out by Rhodamine 123 assay. 
The spectrofluorimetric study revealed a decrease in 
fluorescence spectra with paclitaxel, explaining the 
decreased accumulation of the drug within the cell at 
the isolated resistant subline. This result is in support 
of the previous work of Shatha Abu Hammad, 201336, 
where confirmation has been done by fluorescent cell 
imaging. All these cumulative results along with multi 
drug resistance assay strengthened the notion of 
acquired chemoresistance in the isolated subline 
(MCF-7Pacli/R) of MCF-7. 
Plant-derived natural compounds are reported to 
enhance the cytotoxic effects37 of the 
chemotherapeutic drugs when used in combination. 
These compounds can, therefore, be used along with 
chemotherapeutic drugs for reversing multidrug 
resistance38. Herbal drugs are much cheaper and safer 
for which about 80% of the world’s population relies 
on herbal medicines as primary health care 
support39.These compounds possess strong 
antioxidant properties40,41.  
PEITC, a natural isothiocyanate found in 
cruciferous vegetables has been established as a 
potent anticancer agent due to its wide spectrum of 
biological activities. Compelling evidences, indicated 
the involvement of PEITC in reversing resistance 
towards chemotherapy by regulating several 
molecular pathways32,42,43. Before treatment with 
PEITC, IC30 and IC50 values were determined. To 
assess the role of PEITC in reversing 
chemoresistance, MTT assay was performed. The 
result showed that EC50 of MCF-7 cells to paclitaxel 
was much lower than that of MCF-7Pacli/R cells 
indicating that MCF-7Pacli/R cells had significant 
paclitaxel resistance. PEITC was highly effective in 
reversing acquired chemoresistance as fold reversal 
index increased 5 times in the presence of PEITC.  
For identifying the key molecular event underlying 
chemoresistance, the focus was kept on Aurora A. 
Elevated expression at the protein level and mRNA level 
was detected in MCF-7Pacli/R cells which were associated 
with the accomplishment of chemoresistance. 
Phosphorylation of Aurora A at Thr 288 within the 
kinase activation loop (catalytic domain) increases 
kinase activity. Western blot results demonstrated that in 
untreated cells expression of phospho-Aurora A was 
appreciably high and PEITC efficiently diminished 
phospho-Aurora A expressions in a concentration 
dependent manner which was also reflected in RNA 
expression study, done by RT-PCR. These findings 
cumulatively explained the down regulation of Aurora A 
by PEITC at the transcription level, which was 
paralleled to significant inhibition of phosphorylated 
proteins. Functional activities of Aurora A were reported 
previously to be regulated at the transcriptional level 
and/or at the level of phosphorylation of protein44. The 
present finding, therefore, justified the use of PEITC in 
regulating Auroras. PEITC induced Aurora A inhibition 
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furthermore led to subsequent inhibition of phospho-p53 
(Ser 315) and phospho-IκBα (Ser 32). The results were 
furthermore validated with specific inhibitors of Aurora 
A21,45. Collectively these results supported the 
hypothesis that restoration of chemosensitivity of MCF-
7Pacli/R cells induced by PEITC was associated with 
regulation of Aurora A and its downstream proteins. 
Some apoptotic parameters like TUNEL assay and 
apoptotic indices were studied to ascertain whether 
PEITC induced restoration of chemosensitivity and 
subsequent cytotoxicity due to the regulation of 
Aurora A is occurring through the apoptotic pathway. 
It was observed that treatment with PEITC increases 
the frequency of apoptotic cells which were evident in 
both TUNEL assay and in PI stained cells 
(photograph not shown). PEITC treated cells were 
when subjected to paclitaxel treatment, frequency of 
apoptotic cells was much higher which was reflected 
in calculating apoptotic index values as plotted in the 
graph mentioned in the result section. It was apparent 
that combination treatment gave rise to a better 
impact on both MCF-7 and MCF-7Pacli/R. Present 
findings corroborated with several other studies  
where PEITC was found to induce apoptosis in  
cancer cells46,47. 
Taken together these results established the role of 
PEITC in reversing acquired chemoresistance by 
targeting Aurora A. Regulation of Aurora A by 
PEITC suggestively attributes its role in inducing 
paclitaxel mediated apoptosis. Further mechanistic 
studies are needed to understand the molecular 
interaction of PEITC with Aurora A. 
 
Conclusion 
The result affirmed the contributory role of Aurora-
A in acquirement of paclitaxel resistance in breast 
cancer cells. PEITC by regulating Aurora-A reverses 
chemoresistance and compels cells to undergo 
apoptosis. Therefore PEITC may be considered as a 
potential chemosensitizing agent.  
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